D. Surguladze

发表

Arylphthalazines as potent, and orally bioavailable inhibitors of VEGFR-2.

P. Bohlen, P. Kussie, A. Kiselyov, 2009, Bioorganic & medicinal chemistry.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Manish R. Patel, Charles J. Vaske, Joe Y. Chang, 2016, Journal for Immunotherapy of Cancer.

Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity

J. Haidar, M. Kalos, S. Eastman, 2020, Cancer Immunology Research.

Discovery of 2-Amino-3-amido-5-aryl-pyridines as Highly Potent, Orally Bioavailable, and Efficacious PERK Kinase Inhibitors.

Jennifer R. Wolfley, M. Koszelak-Rosenblum, A. C. Rigby, 2021, Bioorganic & medicinal chemistry letters.

Olaratumab Exerts Antitumor Activity in Preclinical Models of Pediatric Bone and Soft Tissue Tumors through Inhibition of Platelet-Derived Growth Factor Receptor α

B. Rubin, Wayne D. Blosser, M. Dowless, 2017, Clinical Cancer Research.

Prioritization of EGFR/IGF-IR/VEGFR2 combination targeted therapies utilizing cancer models.

D. Hicklin, Zhen-ping Zhu, D. Ludwig, 2009, Anticancer research.

Tumor necrosis factor-alpha and interleukin-1 antagonists alleviate inflammatory skin changes associated with epidermal growth factor receptor antibody therapy in mice.

U. Rodeck, Yan Wu, K. Busam, 2009, Cancer Research.

Antitumor Activity of IMC-038525, a Novel Oral Tubulin Polymerization Inhibitor.

A. Malikzay, P. Kussie, M. C. Tuma, 2010, Translational oncology.

Oxadiazole derivatives as a novel class of antimitotic agents: Synthesis, inhibition of tubulin polymerization, and activity in tumor cell lines.

A. Malikzay, M. C. Tuma, A. Kiselyov, 2006, Bioorganic & medicinal chemistry letters.

A bi-functional antibody-receptor domain fusion protein simultaneously targeting IGF-IR and VEGF for degradation

Zhen-ping Zhu, S. Eastman, Haifan Zhang, 2015, mAbs.

Optimization of a Novel Mandelamide-Derived Pyrrolopyrimidine Series of PERK Inhibitors

A. C. Rigby, M. Betzenhauser, Michael E. Stokes, 2022, Pharmaceutics.

Olaratumab exerts anti-tumor activity in preclinical models of pediatric bone and soft 1 tissue tumors through inhibition of platelet-derived growth factor receptor α in

B. Rubin, Wayne D. Blosser, M. Dowless, 2017 .

Characterization of 7A5: A Human CD137 (4-1BB) Receptor Binding Monoclonal Antibody with Differential Agonist Properties That Promotes Antitumor Immunity

J. Haidar, M. Kalos, Leyi Shen, 2020, Molecular Cancer Therapeutics.

Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054

J. Haidar, M. Kalos, Leyi Shen, 2018, Journal of Immunotherapy for Cancer.

Methods for evaluating effects of an irinotecan + 5-fluorouracil/leucovorin (IFL) regimen in an orthotopic metastatic colorectal cancer model utilizing in vivo bioluminescence imaging.

J. Tonra, D. Surguladze, M. Prewett, 2010, Methods in molecular biology.

Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade

P. Iversen, M. Kalos, G. Plowman, 2018, Journal of Immunotherapy for Cancer.

Anti–Transforming Growth Factor β Receptor II Antibody Has Therapeutic Efficacy against Primary Tumor Growth and Metastasis through Multieffects on Cancer, Stroma, and Immune Cells

Zhen-ping Zhu, Yan Wu, D. Ludwig, 2010, Clinical Cancer Research.

Abstract A091: Targeting the TGFb pathway with galunisertib, a TGFbRI SMI, promotes antitumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint inhibition

M. Kalos, Xiaohong Xu, S. Castaneda, 2016 .

Targeting the TGFβ pathway with galunisertib, a TGFβRI SMI, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint inhibition

M. Kalos, Xiaohong Xu, S. Castaneda, 2015, Journal of Immunotherapy for Cancer.

A human monoclonal antibody targeting the stem cell factor receptor (c-Kit) blocks tumor cell signaling and inhibits tumor growth

K. Persaud, K. Paz, K. Credille, 2014, Cancer biology & therapy.

Intrinsic Resistance to Cixutumumab Is Conferred by Distinct Isoforms of the Insulin Receptor

P. Houghton, Malcolm A. Smith, D. Ludwig, 2015, Molecular Cancer Research.

The Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer Immunotherapy

T. Doman, E. Rasmussen, M. Kalos, 2019, Clinical Cancer Research.

Abstract 955: LY3200882, a novel, highly selective TGFβRI small molecule inhibitor

M. Kalos, Xiaohong Xu, B. Anderson, 2017 .

Pleiotropic stromal effects of vascular endothelial growth factor receptor 2 antibody therapy in renal cell carcinoma models.

H. Youssoufian, Michelle Iacolina, J. Tonra, 2011, Neoplasia.

Removal of a C-terminal serine residue proximal to the inter-chain disulfide bond of a human IgG1 lambda light chain mediates enhanced antibody stability and antibody dependent cell-mediated cytotoxicity

Aiping Zhu, D. Ludwig, Amtul Bari, 2013, mAbs.

Correction to: Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054

J. Haidar, M. Kalos, Leyi Shen, 2018, Journal of Immunotherapy for Cancer.

An antibody directed against PDGF receptor beta enhances the antitumor and the anti-angiogenic activities of an anti-VEGF receptor 2 antibody.

Zhen-ping Zhu, Haifan Zhang, D. Ludwig, 2007, Biochemical and biophysical research communications.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Charles J. Vaske, Joe Y. Chang, Scott R. Presnell, 2016, Journal for ImmunoTherapy of Cancer.

Tumor necrosis factor-alpha and interleukin-1 antagonists alleviate inflammatory skin changes associated with epidermal growth factor receptor antibody therapy in mice.

U. Rodeck, Yan Wu, K. Busam, 2009, Cancer research.